抗PM/Scl抗体阳性系统性硬化症患者的临床表型:EUSTAR队列研究结果
基于EUSTAR数据库的多中心研究比较了144例抗PM/Scl抗体阳性且无SSc特异性抗体的SSc患者与7202例抗PM/Scl抗体阴性患者,并进行了病例对照研究。结果显示抗PM/Scl抗体阳性患者肌肉受累、ILD、钙质沉着和皮肌炎皮肤表现更常见,但硬皮病肾危象和恶性肿瘤频率相似,ILD功能预后较好。
要点
- 抗PM/Scl抗体阳性SSc患者肌肉受累、ILD、钙质沉着和皮肌炎皮肤表现更常见。
- 硬皮病肾危象和恶性肿瘤频率与抗PM/Scl抗体阴性患者相似。
- ILD虽常见但功能预后优于对照,合并SSc特异性抗体者典型SSc特征更频繁。
核心结论
- 抗PM/Scl抗体阳性SSc患者构成以肌肉受累、皮肌炎皮肤表现、钙质沉着和ILD为特征且功能预后良好的特定临床亚群,硬皮病肾危象和恶性肿瘤似不属该综合征。
研究设计与样本
- 分析EUSTAR数据库中144例抗PM/Scl抗体阳性且无SSc特异性抗体的SSc患者,与7202例抗PM/Scl抗体阴性患者比较,并与155例抗PM/Scl抗体阳性且伴SSc特异性抗体患者比较。
- 病例对照研究收集165例抗PM/Scl抗体阳性SSc患者(其中85例来自EUSTAR注册库)的额外数据,与257例按性别、皮肤亚型、疾病病程和SSc发病年龄匹配的抗PM/Scl抗体阴性SSc对照比较。
主要发现
- 与抗PM/Scl抗体阴性患者相比,孤立抗PM/Scl抗体阳性患者肌肉受累、ILD、钙质沉着和皮肌炎皮肤表现频率更高。
- 孤立抗PM/Scl抗体阳性患者硬皮病肾危象和恶性肿瘤(无论是否与SSc发病同步)频率与抗PM/Scl抗体阴性患者相似。
- 肌肉受累与更严重的疾病表型相关。
- ILD虽非常常见,但病例组的功能预后优于对照组。
- 同时具有抗PM/Scl抗体和SSc特异性抗体的患者,典型SSc特征频率高于孤立抗PM/Scl抗体阳性患者。
临床怎么用
- 对SSc患者检测抗PM/Scl抗体有助于识别以肌肉受累、皮肌炎皮肤表现、钙质沉着和ILD为特征且功能预后较好的临床亚群。
- 抗PM/Scl抗体阳性SSc患者仍需关注硬皮病肾危象和恶性肿瘤,但其频率与抗体阴性患者相似,不属该综合征核心表现。
- 合并SSc特异性抗体时典型SSc特征更频繁,临床评估需综合考虑抗体谱。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate clinical associations of anti-PM/Scl antibodies in patients with SSc in a multicentre international cohort, with particular focus on unresolved issues, including scleroderma renal crisis (RC), malignancies, and functional outcome of interstitial lung disease (ILD). METHODS: (1) Analysis of SSc patients from the EUSTAR database: 144 anti-PM/Scl+ without SSc-specific autoantibodies were compared with 7202 anti-PM/Scl-, and then to 155 anti-Pm/Scl+ with SSc-specific antibodies. (2) Case-control study: additional data were collected for 165 anti-PM/Scl+ SSc patients (85 from the EUSTAR registry) and compared with 257 anti-PM/Scl- SSc controls, matched for sex, cutaneous subset, disease duration and age at SSc onset. RESULTS: Patients with isolated anti-PM/Scl+, as compared with anti-Pm/Scl-, had higher frequency of muscle involvement, ILD, calcinosis and cutaneous signs of DM, but similar frequency of SRC and malignancies (either synchronous with SSc onset or not). The presence of muscle involvement was associated with a more severe disease phenotype. Although very frequent, ILD had a better functional outcome in cases than in controls. In patients with both anti-PM/Scl and SSc-specific antibodies, a higher frequency of typical SSc features than in those with isolated anti-PM/Scl was observed. CONCLUSION: The analysis of the largest series of anti-PM/Scl+ SSc patients so far reported helps to delineate a specific clinical subset with muscle involvement, cutaneous DM, calcinosis and ILD characterized by a good functional outcome. SRC and malignancies do not seem to be part of this syndrome.
引用
- Lazzaroni MG, Marasco E, Campochiaro C, et al. The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort. Rheumatology (Oxford). 2021. PMID: 33580257. doi:10.1093/rheumatology/keab152
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。